Get it on Google Play

Keenova doses first patient in Phase 3 hammer toe drug trial

August 20, 2026 7:30 AM EDT Send to a Friend
Keenova Therapeutics plc announced that the first patient has been enrolled and dosed in its Phase 3 clinical trial evaluating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login